Compare FULC & EOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FULC | EOT |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.1M | 242.7M |
| IPO Year | 2019 | 2009 |
| Metric | FULC | EOT |
|---|---|---|
| Price | $3.78 | $15.73 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.67 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 90.6K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.83 | $15.08 |
| 52 Week High | $15.74 | $18.00 |
| Indicator | FULC | EOT |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 47.54 |
| Support Level | $3.75 | $15.08 |
| Resistance Level | $3.81 | $15.76 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 85.29 | 15.00 |
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Eaton Vance National Municipal Opportunities Trust is a diversified, closed-end management investment company. The company's investment objective is to provide current income exempt from regular federal income tax and to achieve capital appreciation. The company invests a majority of its assets in debt obligations issued by or on behalf of states, territories, and possessions of the United States, including the District of Columbia, and their political subdivisions, agencies, or instrumentalities, the interest on which is exempt from regular federal income tax.